Study of patient risk factors for febrile neutropenia in NHL receiving (R)CHOP regimen 2

Study of patient risk factors for febrile neutropenia in NHL receiving (R)CHOP regimen 2 - STOP FN in NHL 2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029534

Enrollment

300

Registered

2017-10-13

Start date

2017-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Hodgkin&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NHL patients received (R)CHOP regimen

Exclusion criteria

Exclusion criteria: HIV related NHL

Design outcomes

Primary

Measure	Time frame
Incidence of FN during the 1st cycle of chemotherapy in NHL patients	—

Countries

Japan

Contacts

Public ContactTomoyuki Nukada

Kyowa Kirin Medical Affairs

ma.oncology@kyowa-kirin.co.jp03-5205-7200

Outcome results